These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 9460860)
21. Production and characterization of neutralizing monoclonal antibodies against poliovirus type 1, 2, and 3. Payment P; Trudel M; Thibodeau L; Lecomte J Can J Microbiol; 1989 May; 35(5):550-3. PubMed ID: 2545322 [TBL] [Abstract][Full Text] [Related]
22. [Status of immunity against poliomyelitis. Polio serosurvey in 1993]. Diedrich S; Schreier E Dtsch Med Wochenschr; 1995 Feb; 120(8):239-44. PubMed ID: 7867480 [TBL] [Abstract][Full Text] [Related]
23. Comparison of the immune response of the rabbit to virulent and attenuated strains of type 1 poliovirus. Gaudin OG; Viac J; Thouvenot D; Sohier R Bull World Health Organ; 1974; 50(6):479-5. PubMed ID: 4376464 [TBL] [Abstract][Full Text] [Related]
24. Vaccine-associated paralytic poliomyelitis. Catton M; Brussen KA; Kennett M Med J Aust; 1996 Feb; 164(4):255-6. PubMed ID: 8604208 [No Abstract] [Full Text] [Related]
25. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073. Kouiavskaia DV; Dragunsky EM; Liu HM; Oberste MS; Collett MS; Chumakov KM Antivir Ther; 2011; 16(7):999-1004. PubMed ID: 22024515 [TBL] [Abstract][Full Text] [Related]
26. How to predict the immune status of poliovirus vaccinees? A comparison of virus neutralization at a very low serum dilution versus ELISA in a cohort of infants. Simhon A; Lifshitz A; Abed Y; Lasch EE; Schoub B; Morag A Int J Epidemiol; 1990 Mar; 19(1):164-8. PubMed ID: 2161806 [TBL] [Abstract][Full Text] [Related]
27. [Enhancing the immunogenicity of inactivated polio vaccines with chitosan used as an adjuvant]. Gendon IuZ; Markushin SG; Akopova II; Krivtsov GG; Akhmatova NK; Koptiaeva IB; Vasil'ev IuM Vopr Virusol; 2011; 56(6):28-32. PubMed ID: 22359946 [TBL] [Abstract][Full Text] [Related]
28. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine. Dragunsky EM; Ivanov AP; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM J Infect Dis; 2006 Sep; 194(6):804-7. PubMed ID: 16941347 [TBL] [Abstract][Full Text] [Related]
29. Poliomyelitis immunity status in Italian and foreign subjects. Tanzi ML; Bracchi U; Affanni P; Dall'Argine A; Bombarda G; Bellelli E Ann Ig; 1992; 4(4):191-7. PubMed ID: 1284576 [No Abstract] [Full Text] [Related]
30. [Characteristics of the dynamics of herd immunity to the poliovirus and of the quality of the vaccination carried out against poliomyelitis]. Vlasova LV; Vaserin IuI; Stepanova GP; Zakirova SF; Venediktova NIa Zh Mikrobiol Epidemiol Immunobiol; 1983 Mar; (3):75-8. PubMed ID: 6303022 [TBL] [Abstract][Full Text] [Related]
31. Seroimmunity to poliomyelitis in an Albanian immigrant population. Squarcione S; Germinario C; Iandolo E; Lo Caputo S; Bergamini F; Profeta ML; Greco D; Quarto M; Barbuti S Vaccine; 1992; 10(12):853-6. PubMed ID: 1333689 [TBL] [Abstract][Full Text] [Related]
32. Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains. Martín J; Crossland G; Wood DJ; Minor PD J Gen Virol; 2003 Jul; 84(Pt 7):1781-1788. PubMed ID: 12810872 [TBL] [Abstract][Full Text] [Related]
33. Surveillance of immunity acquired from poliovirus immunization including vaccination with the Sabin strain-derived inactivated vaccine. Hotta C; Ogawa T; Shirasawa H Hum Vaccin Immunother; 2019; 15(5):1154-1159. PubMed ID: 30676843 [TBL] [Abstract][Full Text] [Related]
34. Evaluation of a two-dose administration of live oral poliovirus vaccine for wild and virulent vaccine-derived poliovirus type 1, 2, 3 strains in Japan. Iwai M; Takizawa T; Nakayama T; Matsuura K; Yoshida H; Hasegawa S; Obara M; Horimoto E; Kurata T; Horie H Scand J Infect Dis; 2008; 40(3):247-53. PubMed ID: 17907043 [TBL] [Abstract][Full Text] [Related]
35. Serological evaluation of poliomyelitis oral and inactivated vaccines in an urban low-income population at Rio de Janeiro, Brazil. Schatzmayr HG; Maurice Y; Fujita M; de Fillipis AM Vaccine; 1986 Jun; 4(2):111-3. PubMed ID: 3014770 [TBL] [Abstract][Full Text] [Related]
36. Intratypic differentiation of poliovirus strains by enzyme-linked immunosorbent assay (ELISA): poliovirus type 1. Glikmann G; Moynihan M; Petersen I; Vestergaard BF Dev Biol Stand; 1983; 55():199-208. PubMed ID: 6203794 [TBL] [Abstract][Full Text] [Related]
37. Epidemiological analysis of immunity to poliovirus after termination of an era of vaccination with OPV in Germany. An analysis of the German Association Against Viral Diseases (DVV). Franck S; Allwinn R; Rabenau HF; Doerr HW Zentralbl Bakteriol; 1999 Oct; 289(4):475-81. PubMed ID: 10603664 [TBL] [Abstract][Full Text] [Related]
38. Anomalous observations on IPV and OPV vaccination. John TJ Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328 [TBL] [Abstract][Full Text] [Related]